EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera

John Mascarenhas, John Mascarenhas, Prithviraj Bose, Christopher Hillis, Abdulraheem Yacoub, Firas El Chaer, Dawn Maze, Ghaith Abu-Zeinah, Albert Qin, Victor Priego, Tsewang Tashi, Sonia Cerquozzi und 16 weitere

Acta Haematologica · 05.03.2025 · 148 (6) · 675-681

DOI: 10.1159/000544818 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Haematologica, online erschienen am 05.03.2025. Verfasst von John Mascarenhas und 27 weiteren Autor:innen. Beteiligte Einrichtung: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Polycythemia Vera, Polyethylene Glycols, Interferon alpha-2, Interferon-alpha. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ropeginterferon alfa-2b-njft (ropeg) was approved and recommended as a preferred cytoreductive treatment for polycythemia vera (PV). The approved regimen requires an initial dose of 100 μg or 50 μg if transitioning from hydroxyurea (HU) and up-titrations of 50 μg every 2 weeks to 500 μg maximumly. The time to achieve the plateau dose takes approximately 20 weeks. This study compares the approved regimen with a higher initial dose and accelerated dose titration (HIDAT) regimen.

Methods

ECLIPSE-PV is a randomized, open-label, multicenter trial in patients with PV in the USA and Canada. Patients received ropeg either per the approved dosing schema or HIDAT regimen, i.e., 250 μg on day 0, 350 μg at week 2, and 500 μg from week 4 thereafter if tolerable. The primary endpoint is complete hematologic response (CHR) rate at week 24. CHR is defined as hematocrit

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycythemia VeraPolyethylene GlycolsInterferon alpha-2Interferon-alphaHumansMaleFemaleMiddle AgedRecombinant ProteinsAgedAdultTreatment Outcome

Stichwörter der Autor:innen

Higher initiating dosePhase 3b clinical trialPolycythemia veraRopeginterferon alfa-2b-njftTwo dosing regimens

Substanzen

Polyethylene GlycolsRecombinant ProteinsInterferon alpha-2peginterferon alfa-2bInterferon-alpha

Autor:innen und Institutionen

  • Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
  • Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas, Missouri, USA.
  • Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, Virginia, USA.
  • Princess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Zitieren

APA

Mascarenhas, J., Mascarenhas, J., Bose, P., Hillis, C., Yacoub, A., El Chaer, F., Maze, D., Abu-Zeinah, G., Qin, A., Priego, V., Tashi, T., Cerquozzi, S., Babu, S., Foltz, L., Goel, S., Bhave, R. R., Lee, S., Oh, S. T., Reeves, B., …, & Masarova, L. (2025). ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera. Acta Haematologica, 148(6), 675-681. https://doi.org/10.1159/000544818

Vancouver

Mascarenhas J, Mascarenhas J, Bose P, Hillis C, Yacoub A, El Chaer F, et al. ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera. Acta Haematologica. 2025;148(6):675-681. doi:10.1159/000544818

BibTeX
@article{Mascarenhas2025,
  author = {Mascarenhas, John and Mascarenhas, John and Bose, Prithviraj and Hillis, Christopher and Yacoub, Abdulraheem and El Chaer, Firas and Maze, Dawn and Abu-Zeinah, Ghaith and Qin, Albert and Priego, Victor and Tashi, Tsewang and Cerquozzi, Sonia and Babu, Sunil and Foltz, Lynda and Goel, Swati and Bhave, Rupali R and Lee, Stephanie and Oh, Stephen T and Reeves, Brandi and Benton, Christopher and Fletcher, Luke and Sirhan, Shireen and Safah, Hana and Salib, Hayman and Villeneuve, Pierre J A and Zagrijtschuk, Oleh and Castro, Henry and Masarova, Lucia},
  title = {ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera},
  journal = {Acta Haematologica},
  year = {2025},
  volume = {148},
  number = {6},
  pages = {675--681},
  doi = {10.1159/000544818}
}
Kostenlos starten →